Windlas Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/02/2026 ,inter alia, to consider and approve To inter alia consider and ....
WINDLAS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Windlas Biotech has informed BSE that its Board of Directors will meet on Thursday, February 5, 2026. The key agenda is to consider and approve the un-audited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (Q3 FY26). The notice is issued under Regulation 29 of SEBI's Listing Obligations and Disclosure Requirements. The company's trading window for designated persons has been closed since January 1, 2026, and will reopen 48 hours after the financial results are announced.
This is a routine pre-results board meeting notice. Shareholders should watch for the Q3 FY26 earnings announcement following the meeting on Feb 5, 2026. The closed trading window signals that results are imminent and insider trading restrictions are in place.